Organic Pressurized Fluid Patents (Class 424/45)
  • Patent number: 10660914
    Abstract: A pharmaceutical composition has a stuffy nose deblocking activity. The composition includes a hyperosmolar aqueous solution of a non-ionic osmolality adjusting agent, optionally in combination with an ionic osmolality adjusting agent, wherein the composition further includes iota-carrageenan and/or kappa-carrageenan as an active antiviral ingredient in an antivirally effective amount, with the proviso that the composition in its ready-for-use formulation contains no more than 0-1.5% w/v of the ionic osmolality adjusting agent. The composition is useful for deblocking a stuffy nose and for prophylactic or therapeutic intervention of a number of viral infections of the upper respiratory tract.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: May 26, 2020
    Assignee: MARINOMED BIOTECH AG
    Inventors: Andreas Grassauer, Eva Prieschl-Grassauer, Angelika Bodenteich, Christiane Koller, Martina Morokutti-Kurz
  • Patent number: 10632266
    Abstract: Described herein are compositions, methods and an apparatus relating to the pulmonary delivery of an inhalable composition comprising caffeine, or a salt thereof, and a solvent selected from the group consisting of propylene glycol, glycerol, ethanol and a combination thereof.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: April 28, 2020
    Assignee: Ahkeo Ventures LLC
    Inventors: Kelly McNeal, Brent Skoda
  • Patent number: 10610512
    Abstract: Provided herein are embodiments related to metered dose inhalers and formulations for such inhalers. In some embodiments, the inhalers are configured so as to allow a more comfortable experience for the subject receiving the formulation. In some embodiments, the formulation comprises various ingredients, such as terpenes and/or waxes, which can further enhance the level of comfort for the subject receiving the formulation.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: April 7, 2020
    Assignee: Island Breeze Systems CA, LLC
    Inventors: Michael S. Hartman, James V. C. Boyles
  • Patent number: 10603268
    Abstract: The present invention relates to a hair composition comprising: (i) one or more polymers containing a silicone unit bearing alkoxy-(aminomethyl)-silyl functional groups; (ii) one or more nonionic fixing polymers and/or one or more anionic fixing polymers.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: March 31, 2020
    Assignee: L'OREAL
    Inventors: Gregory Plos, Nicolas Daubresse, Patrice Lerda, Valerie Favreau
  • Patent number: 10603262
    Abstract: The present invention provides a composition containing component (A): a compound represented by the formula (1) wherein each symbol is as described in the DESCRIPTION, or a salt thereof and component (B): a cationic surfactant, which is superior in the usability during rinsing, which makes the hair surface after treatment smooth and free of dry feeling, provides a uniform touch feeling from the root of the hair to the tip thereof, and can be utilized as an aqueous cosmetic.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: March 31, 2020
    Assignee: AJINOMOTO CO., INC.
    Inventors: Nana Haraya, Shun Kobayashi
  • Patent number: 10576156
    Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 3, 2020
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Patent number: 10576070
    Abstract: Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: March 3, 2020
    Assignee: Arbor Pharmaceuticals, LLC
    Inventor: Hugh Greg Thomas
  • Patent number: 10555903
    Abstract: The present disclosure relates to a nebulization composition comprising tiotropium and formoterol for the treatment of inflammatory or obstructive airway disease. The present disclosure also relates to a process for preparing the composition.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: February 11, 2020
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas R. Dhuppad, Ramprasad Murugan, Mahadeorao S. Rase, Franciscus Koppenhagen, Julianne Berry
  • Patent number: 10525006
    Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: January 7, 2020
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: David Andrew Lewis, Brian John Meakin, Gaetano Brambilla
  • Patent number: 10525005
    Abstract: Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and packs and kits comprising cromolyn are described.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: January 7, 2020
    Assignee: The General Hospital Corporation
    Inventor: David R. Elmaleh
  • Patent number: 10493205
    Abstract: Core annular flow is used to enable the subcutaneous delivery of a viscous fluid such as a protein therapeutic formulation. The high-viscosity fluid is surrounded by a low-viscosity fluid, and the low-viscosity fluid lubricates the passage of the high-viscosity fluid. This allows the use of protein formulations that have a higher concentration and a higher viscosity at comparatively reduced injection forces and reduced injection times. Several different embodiments of injection devices that provide core annular flow are described herein.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: December 3, 2019
    Assignee: Battelle Memorial Institute
    Inventors: Eric C. Scribben, Steven M. Risser, Amy M. Heintz, Jeffrey L. Ellis, John D. Clay, Timothy M. Blum
  • Patent number: 10471040
    Abstract: The present invention relates generally to intranasal pharmaceutical compositions. In particular, the present invention is directed to sustained, enhanced delivery of pharmaceutical agents across the nasal mucosa for systemic drug delivery.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: November 12, 2019
    Assignee: Lachesis Biosciences Limited
    Inventor: Timothy Matthias Morgan
  • Patent number: 10449161
    Abstract: The invention provides microparticles for use in a pharmaceutical composition for pulmonary administration, each microparticle comprising a particle of an active substance having, on its surface, particles of a hydrophobic material suitable for delaying the dissolution of the active substance. The invention also provides a method for making the microparticles.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: October 22, 2019
    Assignee: VECTURA LIMITED
    Inventors: John Nicholas Staniforth, Haggis Harris, David Alexander Vodden Morton, Robin Bannister
  • Patent number: 10441552
    Abstract: This invention discloses anti-bacterial and anti-fungal compositions in spray form, in cream form, in liquid form, and in powder form. The anti-bacterial and anti-fungal compositions comprise cannabinoids, specifically cannabidiol, cannabigerol, tetrahydrocannabinol, tetracannabidivarin, and/or cannabidivarin for anti-bacterial and anti-fungal activities. The anti-bacterial and anti-fungal compositions may be used to treat toe nail fungus, MRSA infection, herpes virus infection, tinea pedis, burn wound infections, sun burns, diabetic infections, eczema, impetigo, dermatophytosis, psoriasis, itchy skin, atopic dermatitis, dandruff, and general topical infections.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: October 15, 2019
    Assignee: Axim Biotechnologies, Inc.
    Inventors: George E. Anastassov, Lekhram Changoer, Philippus Anne Van Damme
  • Patent number: 10426713
    Abstract: A method of treating hair or skin with a creamy foam. The method comprises dispensing a personal care composition from a mechanical foam dispenser as a dosage of foam, applying the dosage of foam to hair or skin, and rinsing the dosage of foam from hair or skin. The personal hair composition contains a surfactant system that is substantially free of sulfate-based surfactants. The personal hair composition has a viscosity of less than 60 cP and a lather volume greater than 77 cm3.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: October 1, 2019
    Assignee: The Procter and Gamble Company
    Inventors: Brian Xiaoqing Song, Ioannis Constantine Constantinides
  • Patent number: 10415001
    Abstract: The invention relates to mixtures having: components (a) having at least one fragrance of the formula (I) where R1=OC—R2, CH2OR3, C1-C8 open-chain or branched aliphatic radical, optionally substituted and/or unsaturated, with R2=an open-chain or branched aliphatic radical, optionally substituted and/or unsaturated, having 2-10 C atoms, with R3=an open-chain or branched aliphatic radical, optionally substituted and/or unsaturated, having 1-8 C atoms, and components (b) having at least one fragrance, different from the fragrances of component a, characterized in that the weight ratio of all components (a) to all components (b) is from 1:10 to 1:10000.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: September 17, 2019
    Assignee: SYMRISE AG
    Inventors: Erich Dilk, Edison Diaz, Pierre Kurzenne, Walter Kuhn
  • Patent number: 10398656
    Abstract: A composition comprising dimethyl sulfoxide (DMSO) as an effective agent useful for treating skin diseases or conditions caused by, associated with, or are complicated by microbial infection is disclosed.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: September 3, 2019
    Assignee: Veloce BioPharma, LLC
    Inventors: Nicholas J. Caramenico, III, Joseph Capriotti, Kara Capriotti
  • Patent number: 10376526
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: August 13, 2019
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas R. Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
  • Patent number: 10376525
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: August 13, 2019
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • Patent number: 10369102
    Abstract: Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: August 6, 2019
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Rita Keynan, David Schuz, Tal Berman
  • Patent number: 10350149
    Abstract: Anhydrous antiperspirant composition in aerosol form comprising an antiperspirant active agent and a water-insoluble film-forming block ethylenic polymer The present invention relates to an anhydrous composition in aerosol form containing: i) an oily phase comprising, in a physiologically acceptable medium: —at least one volatile oil, and —one or more antiperspirant active agents chosen from aluminum and/or zirconium salts, and —one or more water-insoluble film-forming block ethylenic polymers comprising a first block with a glass transition temperature (Tg) of greater than or equal to 85° C. and a second block with a Tg of less than or equal to 20° C., and ii) one or more propellants; the said oily phase containing less than 15% by weight and even more preferably less than 12% by weight of non-volatile polydimethylsiloxane relative to the total weight of the oils.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: July 16, 2019
    Assignee: L'Oreal
    Inventors: Odile Aubrun, Xavier Jalenques, Laurence Sebillotte-Arnaud
  • Patent number: 10350166
    Abstract: A substantially surface active agent-free and substantially polymeric agent-free foamable composition is disclosed, which includes short-chain alcohol, water, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. Also disclosed is a method of treatment by applying the substantially surface active agent-free and substantially polymeric agent-free foamable composition.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: July 16, 2019
    Assignee: FOAMIX PHARMACEUTICALS LTD.
    Inventors: Dov Tamarkin, Enbal Ziv, Yohan Hazot, David Schuz
  • Patent number: 10342787
    Abstract: Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: July 9, 2019
    Assignee: ARBOR PHARMACEUTICALS, LLC
    Inventor: Hugh Greg Thomas
  • Patent number: 10342820
    Abstract: The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: July 9, 2019
    Assignee: MARINOMED BIOTECH AG
    Inventors: Andreas Grassauer, Eva Prieschl-Grassauer
  • Patent number: 10342806
    Abstract: Permanent hearing loss or deafness affects about 15% of people worldwide, about 40 million in the US alone. There are currently no FDA-approved drugs on the market in the US, or anywhere in the world that prevent, treat or reverse permanent hearing loss or deafness. Age-related hearing loss (ARHL) is one of the most common forms of permanent hearing loss and deafness. ARHL is the #1 neurodegenerative disorder, #1 communication disorder, and 1 of the top 3 chronic medical conditions (along with arthritis & cardiovascular diseases) of our aged population. The incidence of ARHL is increasing due to the “Baby Boomers” reaching old age, and cumulative effects of lifetime noise exposure, and widespread use of chemotherapeutic and antibiotic drugs, which are ototoxic, or have ototoxic side effects. A new drug is disclosed to prevent or slow the progression of ARHL, based upon natural, existing FDA-approved compounds that are on the market to treat other non-ARHL biomedical problems.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: July 9, 2019
    Assignee: University of South Florida
    Inventors: Robert Dana Frisina, Joseph Paul Walton, Bo Ding, Xiaoxia Zhu
  • Patent number: 10342938
    Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: July 9, 2019
    Assignee: MannKind Corporation
    Inventors: Chad C. Smutney, Benoit Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl R. Sahi, Christine Billings, Mark T. Marino
  • Patent number: 10336868
    Abstract: Methods of selectively modifying lignin, polycarboxylated products thereof, and methods of deriving aromatic compounds therefrom. The methods comprise electrochemically oxidizing lignin using stable nitroxyl radicals to selectively oxidize primary hydroxyls on ?-O-4 phenylpropanoid units to corresponding carboxylic acids while leaving the secondary hydroxyls unchanged. The oxidation results in polycarboxylated lignin in the form of a polymeric ?-hydroxy acid. The polymeric ?-hydroxy acid has a high loading of carboxylic acid and can be isolated in acid form, deprotonated, and/or converted to a salt. The ?-hydroxy acid, anion, or salt can also be subjected to acidolysis to generate various aromatic monomers or oligomers. The initial oxidation of lignin to the polycarboxylated form renders the lignin more susceptible to acidolysis and thereby enhances the yield of aromatic monomers and oligomers obtained through acidolysis.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: July 2, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Shannon S. Stahl, Mohammad Rafiee
  • Patent number: 10335435
    Abstract: A method is disclosed for delivery of stem cells to the central nervous system, particularly the brain, using an intranasal, injectable approach for the treatment of neurological deficits. The injectable approach employs a syringe to inject a stem cell solution or suspension into mucosal tissue of the nose using endoscopy. The approach provides direct endoscopic visual access to mucosal and sub-mucosal tissue selected for injection and the depth of placement of stem cells within the selected mucosal and sub-mucosal tissue. Placement of stem cells solely within the mucosal and sub-mucosal tissue assures survival of the stem cells and improves the likelihood the stem cells will reach specific sites of damage within the brain. This endoscopic intranasal approach is useful as therapy for patients who may benefit from cellular therapy as a result of stroke, brain trauma, and neurodegenerative conditions.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: July 2, 2019
    Inventor: Marco Merida
  • Patent number: 10335538
    Abstract: A treatment method that increases circulation and pluripotency of stem and progenitor cells within a patient can be used to fight off or cure various diseases for the patient such as chronic kidney disease or end-stage renal disease. An administrator of the treatment method is provided with a medicinal-administration system such as an intravenous injection system. The treatment method begins by preparing a dosage of oxygen-ozone mixture with the medicinal-administration system. The medicinal-administration system then transfuses the oxygen-ozone mixture in the patient's bloodstream so that the renal system and/or the bone marrow can be targeted by the oxygen-ozone mixture. These steps are repeated as a plurality of treatment session for the patient.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: July 2, 2019
    Inventor: Priya Visweswaran Balakrishnan
  • Patent number: 10328216
    Abstract: A method of manufacturing a flowable and dispersible powder includes solubilizing a lipophilic substance in a terpene to form a mixture and treating the mixture to form a nanoemulsion dispersed in an aqueous solution. The aqueous solution includes at least one functional excipient. The nanoemulsion is then spray dried, thereby evaporating first the aqueous portion and then the terpene to form a dry powder formed from solid particles comprising the lipophilic substance.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: June 25, 2019
    Assignee: Flurry Powders, LLC
    Inventors: Andrew John Boeckl, David Edward Cookson
  • Patent number: 10323064
    Abstract: The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or treating bone diseases, including the novel peptide. The novel peptide according to the present disclosure induces mobilization of hematopoietic stem cells to blood and causes a decrease in the number of osteoclasts, and, thus, decreases bone erosion caused by osteoclasts, thereby suppressing progress of an osteoporotic lesion. Further, the novel peptide is safe since it does not cause rejection in the body. Furthermore, since the novel peptide is formed of 16 short amino acids, a low dose of the peptide can relieve symptoms of osteoporosis.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: June 18, 2019
    Assignee: Kyungpook National University Industry—Academic Cooperation Foundation
    Inventors: Jae Sung Bae, Hee Kyung Jin, Min Hee Park
  • Patent number: 10314785
    Abstract: The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: June 11, 2019
    Assignee: NORTON HEALTHCARE LTD
    Inventors: Adrian Ashley, Paul Lamb, Donald MacDonald, John Miller, Martin J. Oliver, Mathew Pollard
  • Patent number: 10307342
    Abstract: There is provided an oral biofilm inhibitor having an exceptional inhibitory effect on oral biofilm formation. It is an oral biofilm inhibitor comprising a curable composition containing an antimicrobial agent, wherein a compressive strength of a cured product formed by curing the composition is 150 MPa or less, and a content of the antimicrobial agent is 0.001 to 3% by weight. An oral biofilm inhibitor thus obtained is used for inhibiting biofilm formation in an oral cavity by applying a curable composition containing an antimicrobial agent to a dental defect site for allowing the composition to cure at the dental defect site, and then disintegrating the cured composition.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: June 4, 2019
    Assignee: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
    Inventors: Kazuhiro Omori, Takashi Ito, Shogo Takashiba, Masao Irie
  • Patent number: 10301255
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A1-Y-A2-Z-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: May 28, 2019
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Yao-Ling Qiu, Wei Li, Hui Cao, Meizhong Jin, Jorden Kass, Xuri Gao, Xiaowen Peng, Yat Sun Or
  • Patent number: 10279046
    Abstract: The present invention relates to a composition for treating an ocular inflammatory disease, comprising hydrophilic sulfasalazine and hyaluronic acid, and a preparation method therefor. Furthermore, the present invention relates to a method for treating an ocular inflammatory disease, which comprises administering, to an individual, a therapeutically effective amount of hydrophilic sulfasalazine and hyaluronic acid.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: May 7, 2019
    Assignee: CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Choun-Ki Joo, Jun-Sub Choi
  • Patent number: 10258568
    Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: April 16, 2019
    Assignee: MEXICHEM AMANCO HOLDINGS S.A. DE C.V.
    Inventors: Stuart Corr, Timothy James Noakes
  • Patent number: 10258547
    Abstract: The present invention relates to a cosmetic composition in the foam form comprising, in a physiologically acceptable medium, at least one aqueous phase, talc and one UV sunscreen ingredient. It also relates to a cosmetic composition in the foam form comprising, in a physiologically acceptable medium, at least one aqueous phase, at least 1% by weight of at least one mineral filler relative to its total weight, and one UV sunscreen ingredient.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: April 16, 2019
    Assignee: L'OREAL
    Inventor: Takehiko Kasai
  • Patent number: 10258569
    Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: April 16, 2019
    Assignee: MEXICHEM AMANCO HOLDINGS S.A. DE C.V.
    Inventors: Stuart Corr, Timothy James Noakes
  • Patent number: 10251900
    Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: April 9, 2019
    Assignee: INSMED INCORPORATED
    Inventors: Gina Eagle, Renu Gupta
  • Patent number: 10238697
    Abstract: The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: March 26, 2019
    Assignee: ARES TRADING S.A.
    Inventors: Philippe Langella, Jean-Marc Chatel, Luis Bermudez-Humaran, Camille Aubry, Laurence Goffin, Simone Favre-Zimmerli, Yolande Chvatchko
  • Patent number: 10226483
    Abstract: The present invention generally relates to topical compositions and methods of using the same. The topical compositions may comprise a hydrophilic composition and a hydrophobic composition in admixture. The hydrophobic composition may include a nitric oxide-releasing compound such as, for example, a diazeniumdiolate functionalized co-condensed silica particle. In some embodiments, the topical composition may be self-emulsifying. Further described herein are kits comprising a hydrophilic composition and a hydrophobic composition.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: March 12, 2019
    Assignee: Novan, Inc.
    Inventors: Ryan Doxey, Jian Bao
  • Patent number: 10201672
    Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: February 12, 2019
    Assignee: MannKind Corporation
    Inventors: Chad C. Smutney, P. Spencer Kinsey, Carl R. Sahi, Benoit Adamo, John M. Polidoro, Scott McLean, Dennis Overfiled, Anthony Bryant
  • Patent number: 10195139
    Abstract: Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties, and physiologically active substance.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: February 5, 2019
    Assignee: Shin Nippon Biomedical Laboratories, Ltd.
    Inventors: Ryoichi Nagata, Shunji Haruta
  • Patent number: 10179145
    Abstract: A hemostatic tissue sealant sponge and a spray for acute wounds are disclosed. The sponge comprises hydrophobically modified polymers that anchor themselves within the membrane of cells in the vicinity of the wound. The seal is strong enough to substantially prevent the loss of blood inside the boundaries of the sponge, yet weak enough to substantially prevent damage to newly formed tissue upon recovery and subsequent removal of the sponge. In examples, the polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The spray comprises hydrophobically modified polymers that form solid gel networks with blood cells to create a physical clotting mechanism to prevent loss of blood. In an example, the spray further comprises at least one reagent that increases the mechanical integrity of the clot. In another example, the reagent prevents microbial infection of the wound.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: January 15, 2019
    Assignees: University of Maryland, College Park, University of Maryland, Baltimore
    Inventors: Matthew Dowling, John Hess, Grant Bochicchio, Srinivasa Raghavan
  • Patent number: 10179139
    Abstract: Described herein is a pharmaceutical composition that includes a beta2-agonist selected from indacaterol and formoterol in combination with a corticosteroid selected from fluticasone and ciclesonide, and, optionally, one or more pharmaceutically acceptable excipients.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: January 15, 2019
    Assignee: CIPLA Limited
    Inventors: Geena Malhotra, Shrinivas Madhukar Purandare
  • Patent number: 10166247
    Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: January 1, 2019
    Assignee: AstraZeneca AB
    Inventors: Nayna Govind, Maria Marlow
  • Patent number: 10166268
    Abstract: The present disclosure provides methods for treating obstructive sleep apnea (OSA) and OSA induced cardiorespiratory diseases. The disclosure provides, inter alia, methods for treating or alleviating: OSA or OSA induced hypertension, cardiac arrhythmias, myocardial ischemia, sudden cardiac death or stroke, by administering oxytocin. The disclosure further provides methods for improving sleep satisfaction in OSA patients by administering oxytocin.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: January 1, 2019
    Assignee: THE GEORGE WASHINGTON UNIVERSITY
    Inventors: David Mendelowitz, Vivek Jain, Heather Jameson, Jay Shawn Kimbro
  • Patent number: 10159769
    Abstract: Methods of making medical devices are described. A method of making a medical device for delivering a bioactive includes preparing a suitable solution comprising the bioactive; placing a vessel containing the solution over a substrate comprising a biocompatible foam and defining open cells; initiating flow of the solution from the vessel and toward the substrate such that the solution exits the vessel and contacts the substrate; and maintaining flow of the solution for an amount of time sufficient to achieve a desired volume of the solution within the substrate. Medical devices made by the methods are also described.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: December 25, 2018
    Assignee: Cook Medical Technologies LLC
    Inventor: Colleen Gemborys
  • Patent number: 10139321
    Abstract: The present disclosure relates to a mucolytic tablet for a sample collection device that causes mucolysis of biological samples collected in the sample collection device. The mucolytic tablet includes N-acetyl L-cysteine (NALC), a pharmaceutically active mucolytic agent that reduces the viscosity of mucus containing biological samples. The mucolytic tablet also includes one or more chelating agents, water-soluble anti-adherent/s, and at least one buffering agent.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: November 27, 2018
    Assignee: Alpha-Tec Systems, Inc.
    Inventors: Richard Williams, Anne Frontella, Mark Williams
  • Patent number: 10130573
    Abstract: The present invention is a composition and method of treatment for skin disorders, conditions, and severe skin dryness in general through topical systematic and periodic application of a formulation that generally may include salicylic acid, glycolic acid, urea, dimethyl isosorbide, ethoxydiglycol, barrier repair agents, anti-irritants, humectants, and also has an acidic pH formulation.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: November 20, 2018
    Assignee: Clark Pharmaceuticals LLC
    Inventors: Stephen W. Clark, Natalie Barger